# SARS-CoV-2 sequencing with cloud-based analysis illustrates expedient co-ordinated surveillance of viral genomic epidemiology across six continents

3

## 4 Authors

5	Daniel Amoako, <sup>1</sup> Nguyen To Anh, <sup>2</sup> Marc Brouard, <sup>3</sup> Constanza Campano Romero, <sup>4</sup> Andres
6	Castillo Ramirez, <sup>4</sup> Bede Constantinides, <sup>3</sup> Derrick Crook, <sup>3,5</sup> Phan Manh Cuong, <sup>6</sup> Moussa
7	Moise Diagne, <sup>7</sup> Amadou Diallo, <sup>7</sup> Nguyen Thanh Dung, <sup>8</sup> Laura Dunn, <sup>5</sup> Le Van Duyet, <sup>6</sup> Josie
8	Everatt, <sup>1</sup> Katherine Fletcher, <sup>3</sup> Philip Fowler, <sup>3</sup> Mailie Gail, <sup>9</sup> Hospital for Tropical Diseases
9	SARS-CoV-2 testing team, <sup>8</sup> Nguyen Thi Thu Hong, <sup>2</sup> Martin Hunt, <sup>3,11</sup> Zam Iqbal, <sup>3,11</sup> Katie
10	Jeffery, <sup>5</sup> Dikeledi Kekana, <sup>1</sup> Thomas Kesteman, <sup>2</sup> Jeff Knaggs, <sup>3,11</sup> Marcela Lopes Alves, <sup>3</sup> Dinh
11	Nguyen Huy Man, <sup>8</sup> Amy J. Mathers, <sup>10</sup> Nghiem My Ngoc, <sup>8</sup> Sarah Oakley,5 Hardik Parikh, <sup>10</sup>
12	Tim Peto, <sup>3,5</sup> Marcelo Rojas Herrera, <sup>4</sup> Nicholas Sanderson, <sup>3</sup> Vitali Sintchenko, <sup>9</sup> Jeremy
13	Swann, <sup>3</sup> Nguyen Thi Tam, <sup>2</sup> Le Van Tan, <sup>2</sup> Pham Ngoc Thach, <sup>6</sup> Ndeye Marieme Top, <sup>7</sup> Nguyen
14	Thu Trang, <sup>2</sup> Van Dinh Trang, <sup>6</sup> H. Rogier Van Doorn, <sup>2</sup> Anne von Gottberg, <sup>1,12</sup> Nicole
15	Wolter, <sup>1,12</sup> Bernadette C Young <sup>3,5</sup>
16	
17	Affiliations
18	1. The National Institute for Communicable Diseases (NICD), a division of the National
19	Health Laboratory Service, Johannesburg,, Republic of South Africa
20	2. Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
21	3. Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
22	4. El Instituto de Salud Pública de Chile, Chile
23	5. Oxford University Hospitals NHS Trust, Oxford, United Kingdom
24	6. National Hospital for Tropical Diseases, Hanoi, Vietnam
25	7. The Institut Pasteur de Dakar, Senegal
26	8. Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
27	9. Microbial Genomics Reference Laboratory, Institute of Clinical Pathology and
28	NOTE: This predictal Bris new research was not been certified by the review and should be used stratige clinical practice.

- 29 10. Division of Infectious Diseases, School of Medicine, University of Virginia,
- 30 Charlottesville, United States of America
- 31 11. European Bioinformatics Institute, Hinxton, UK
- 32 12. Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South
- 33 Africa
- 34
- 35 Corresponding author: Bernadette Young (Bernadette.young@ndm.ox.ac.uk)
- 36
- 37

## 38 Abstract

39 Viral sequencing has been critical in the COVID-19 pandemic response, but sequencing and 40 bioinformatics capacity remain inconsistent. To examine the utility of a cloud-based 41 sequencing analysis platform for SARS-CoV-2 sequencing, we conducted a cross-sectional 42 study incorporating seven countries in July 2022. Sites submitted sequential SARS-CoV-2 43 sequences over two weeks to the Global Pathogen Analysis Service (GPAS). The GPAS 44 bioinformatics cloud platform performs sequence assembly plus lineage and related sample 45 identification. Users can share information with collaborators while retaining data ownership. 46 Seven sites contributed sequencing reads from 5,346 clinical samples, of which 4,799/5,346 47 (89.8%) had a lineage identified. Omicron lineages dominated, with the vast majority being 48 BA.5, BA.4 and BA.2, commensurate with contemporary genomic epidemiological observations. Phylogenetic analysis demonstrated low within-lineage diversity, and highly 49 50 similar sequences present in globally disparate sites. A cloud-based analysis platform like 51 GPAS addresses bioinformatics bottlenecks and facilitates collaboration in pathogen 52 surveillance, enhancing epidemic and pandemic preparedness. 53 54 55

## 57 Introduction

58 Viral genomic sequencing has been pivotal in understanding and responding to SARS-CoV-2 59 viral evolution during the COVID-19 pandemic. Global sharing of data and comparison of 60 samples has facilitated public health surveillance by tracking the emergence of variants 61 globally,[1] demonstrating the impact of travel restrictions on viral dynamics across 62 continents, [2] and of travel and guarantine on spread within countries, [3,4] as well as 63 demonstrating transmission routes within hospitals.[5] As successive waves driven by new 64 viral variants emerged, it became clear that rapidly detecting new lineages is critical both for 65 understanding and predicting disease epidemiology as well as for guiding both public health 66 measures and treatment of infection, including the use of neutralising antibodies.[6,7] However there remains marked global variability in sequencing costs and capacity.[8] Much 67 68 SARS-CoV-2 sequencing has been undertaken at centralised reference laboratories, but the 69 speed and power of this tool is greatly enhanced when researchers and clinicians at any 70 location can contribute to the global view of viral evolution and surveillance.[9]

71

Several important challenges remain in expanding pathogen genomic surveillance, including 72 73 access to sequencing technology, the availability of bioinformatic resources and the global 74 interpretability of results generated using different bioinformatics approaches.[10,11,12] One 75 solution to the relative shortage of bioinformatic expertise in many settings is web-accessible 76 analysis infrastructure.[13] The Global Pathogen Analysis Service (GPAS) is a cloud-based globally web-accessible platform that provides secure and rapid access to comprehensive 77 78 SARS-CoV-2 sequencing genome assembly and analysis software. GPAS supports multiple 79 sequencing platforms and tiling PCR primer schemes, and has been validated against widely 80 used methods. Users can opt to share their data on this platform, allowing those who opt in to 81 view their own results in a wider context, facilitating comparisons for rapid and 82 comprehensive assessments of viral data. The platform is designed for use by clinical and 83 public health laboratory scientists and has been established and used for over a year in a 84 tertiary hospital based clinical microbiology laboratory to ISO15189:2012 standards. Scaling

up this simple-to-use assembly, variant calling and analysis tool for SARS-CoV-2 empowers
laboratories to control the analysis of their sequence data. It provides proof of principle that
standard microbiology laboratories without bioinformatics expertise from across the world
can generate outputs for local surveillance and automated submission to public databases.
Such a service is an exemplar of how cloud-based services, accessible in all settings with
internet access, offer great promise for overcoming an important barrier to effective genomic
surveillance.

92

93 The primary aim of this project was to demonstrate that a globally broad snapshot of SARS-

94 CoV-2 viral diversity can be simultaneously gathered, processed and shared through a cloud-

95 based software, enabling aggregation for combined descriptive analysis.

96

## 97 Methods

98 Sample frame and sequencing: Sequencing centres participated in a two-week pilot in July to

99 August 2022. Centres were from seven countries: Senegal; Chile; South Africa; New South

100 Wales (NSW), Australia; Vietnam; United Kingdom; Virginia, United States (USA). Centres

101 were either accredited clinical microbiology or public health laboratories. All clinical

102 samples in which SARS-CoV-2 was detected were eligible for inclusion and underwent in-

103 house genomic sequencing at participating sites during the pilot were eligible for inclusion,

104 with no more than one submission from an individual patient.

105

106 Sequencing was performed using either Illumina or Oxford Nanopore Technology (ONT)

107 platforms. Multiple primer schemes were supported (ARCTIC V3, V4 or 4.1, and Midnight).

108 Sequencing platform and primer schemes were chosen by participating sites, who followed

109 their established sequencing protocols.

110

Bioinformatic methods: Unselected raw sequences were submitted to GPAS in FASTQ
format with sequencing information (instrument platform, primer scheme) and limited

113 associated metadata (sample name, whether sequence data was a control or study sample, 114 collection date, country of origin). At upload, a Universally Unique IDentifier (UUID) was randomly generated and assigned to each sample. The mapping between the centre's sample 115 116 identifier and the GPAS UUID was held only by the submitting organisation, ensuring that no 117 potentially personally identifiable information was transmitted to the GPAS platform. When 118 results were returned to the submitter after analysis, they could hence be re-linked to the subject's record. At upload, only reads mapping to SARS-CoV-2 were kept, [14] guaranteeing 119 120 that no human reads were retained and pushed to the cloud. Tight access control to data 121 applied within GPAS. With the permission of all collaborators, data access controls were 122 configured such that all submitters could access each other's sequences, metadata and 123 analytical output data for the duration of the investigation.

124

125 Sequence data analysis was performed by the GPAS SARS-CoV-2 bioinformatics pipeline. Genome assembly was performed by an amplicon-aware *de novo* genome assembly tool 126 127 Viridian v0.3.7.[15] Viridian applies quality control (QC) at both a read and amplicon level, to produce a consensus assembly. Each genomic position is called A,C,G or T only where 10 128 129 or more reads passing amplicon-aware QC provide at least 70% support, otherwise it is called 130 ambiguously as N. After assembly, clade assignment and amino acid mutation calls were 131 made using Nextclade, [16] and Pango lineages assigned with Pangolin. [17] Samples were 132 further labelled according to the United Kingdom Health Security Agency (UKHSA) nomenclature to define and track variants of concern using aln2type.[18] The GPAS QC suite 133 134 provided read-level QC output for each sample, reporting the number of mapped reads per 135 sample, median read depth, reference coverage at read depths of 10 and 20, and the number 136 of amplicons failing quality control. Consensus genome assemblies were aligned by Viridian to the Wuhan-Hu-1 reference genome (MN908947.3).[19] Aligned sequences were compared 137 138 using findNeighbour4, which identifies sequences without conflicting variant calls (0 single 139 nucleotide variants (SNVs)), as well as those differing by one, two and three SNVs.[20,21]

141 Submitting sites verified the run quality reports of each sequencing batch, including review 142 of positive and negative controls, and outputs were passed or failed accordingly. All passed 143 samples were tagged for aggregate analysis, and released to the GPAS shared data pool, 144 which identifies other samples within three SNVs in the shared data pool. The GPAS platform recorded the total number of sequencing runs and total number of samples. Analysis 145 146 duration was also monitored, along with descriptive reports of any unexpected issues with the 147 platform. 148 149 Phylogenetic analysis: In Oxford, genome assemblies in the shared data pool were 150 downloaded from the GPAS portal. A maximum likelihood phylogeny of aligned sequences 151 was constructed for the three largest Pango lineages in the sample set (BA.5, BA.4 and BA.2) 152 in using RAxML [22] (assuming a general time reversible (GTR) nucleotide substitution

153 model).

154

## 156 **Results**

- 157 All sites tagged their sequencing data and results granting access for aggregated analysis.
- 158 5,437 sequences were shared (Table 1, Table S1). As different sequencing centres worked
- 159 with samples collected at different times, the date of collection of submitted sequences varied
- 160 by centre, ranging from April to July 2022. Of submitted samples 91 (1.7%) were controls
- 161 and 5,346 (98.3%) were clinical samples Among these, 4,797/5,346 (89.7%) were assembled
- 162 with at least 70% coverage (at a depth of 10 reads), and 4,799/5,346 (89.8%) were assembled
- 163 with sufficient coverage to be assigned a lineage (Table 2). 4,775/4,799 (99.5%) were
- 164 Omicron variants, with BA.5, BA.4 and BA.2 being the most common. A small number of
- 165 Delta variant sequences were identified (23/4,799 0.5%), all of which were collected prior to
- 166 July 2022.

167

- 168 Table 1: Samples submitted by study centre, with date of collection and genome coverage
- 169 (with minimum depth of 10 reads)

Centre	Submitted	Controls	<50% coverage	50-70% coverage	>70% coverage	Earliest sequence	Latest sequence
Senegal	197	0	14	10	173	13 <sup>th</sup> July 2022	20 <sup>th</sup> July 2022
Chile	1205	20	4	7	1174	16 <sup>th</sup> June 2022	21 <sup>st</sup> July 2202
South Africa	202	0	9	4	189	17 <sup>th</sup> May 2022	24 <sup>th</sup> June 2022
NSW, Australia	1194	31	34	23	1106	21 <sup>st</sup> June 2022	18 <sup>th</sup> July 2022
Vietnam	316	3	20	5	288	1 <sup>st</sup> April 2022	14 <sup>th</sup> July 2022
United Kingdom	1823	37	319	100	1367	12 <sup>th</sup> July 2022	26 <sup>th</sup> July 2022
Virginia, USA	500	0	0	0	500	7 <sup>th</sup> June 2022	29 <sup>th</sup> June 2022
Total	5437	91	400	149	4797	1 <sup>st</sup> April 2022	26 <sup>th</sup> July 2022

- 170
- 171
- 172
- 173

174

	Omicron								Alpha	Other	
Centre	BA.5	BA.4	BA.2	BE.1	BF.1	BA.1	BG.2	Delta	B.1.1.7	B.28	Total
Senegal	69	47	34	5	18	0	0	0	0	0	173
Chile	397	607	145	20	4	0	0	0	0	0	1,173
South Africa	89	86	3	6	0	5	0	0	0	0	189
NSW, Australia	736	130	184	54	3	0	0	0	0	0	1,107
Vietnam	8	0	256	0	0	4	0	22	0	0	290
United Kingdom	974	169	57	140	23	2	0	0	1	1	1,367
Virginia, USA	95	94	296	11	1	1	1	1	0	0	500
Total	2,368	1,133	975	236	49	12	2	23	1	1	4,799

#### 176 Table 2: SARS-CoV-2 lineage by study centre (where a lineage was assigned by Pangolin)

177

178 Comparing only clinical samples collected between 1<sup>st</sup> June 2022 and 31st July 2022, the

179 proportion of samples assigned to the different Omicron sub-lineages varied substantially by

180 study site (Figure 1). Each of BA.2, BA.4 or BA.5 dominated (constituted >50% of samples

181 from) at least one site, while Senegal had no single dominant lineage. For each of the three

182 most common lineages, a maximum likelihood phylogeny was constructed to compare

183 diversity within and between sites (Figure 2).

184

Phylogenetic analysis revealed global mixing of Omicron lineages. There were no examples of sub-lineages being completely geographically restricted within this study. One sub-lineage in BA.4 was predominantly found in Chile (Figure 2), however examples of this sub-lineage were also identified in the United Kingdom. Similarly, a sub-lineage of BA.2 was mainly found in Vietnam (Figure 2) but again an example of this genotype was found in the United Kingdom.

191

Highly genetically similar samples were identified within lineages from globally distinct sites, with branch lengths corresponding to  $\leq 0.01\%$  of the genome (approximately three nucleotides) separating many samples. This limited diversity was further explored by examining the relative likelihood of samples being from the same site with increasing genomic variation. By this measure, the greatest dispersal was seen within the BA.4 lineage

197 (Figure 3). In total 357/1,133 of BA.4 samples were genotypically identical to another 198 sequenced sample. Among these, 244/357 (68.4%) were only identical to other samples from 199 the same study centre. Allowing for just one single nucleotide variant (SNV) reduced the 200 proportion of closely related samples to the same study centre (and country) to 302/634 201 (47.6%). The proportions reduced to 279/819 (34.1%) and to 201/923 (21.8%) when allowing 202 for two and three SNVs respectively. Only 210/1,133 (18.5%) did not have a related sample allowing up to three SNVs. The other major lineages BA.2 and BA.5 likewise showed 203 204 evidence of genotypically identical sequences identified at different study sites, with 205 increasing evidence of dispersal as SNV threshold increased (Figure 3). 206

207 Cloud processing performance was measured by time elapsed from upload until completion 208 of processing. The median sample processing time was 30.6 minutes (IQR 13.1-69.9 209 minutes). The distribution of processing times was much wider than expected, and processing 210 delays occurred for several batches from Australia, United Kingdom and United States 211 (Figure S1). Some of these coincided with data centre outages during an extreme heat event 212 in the United Kingdom, while other delays occurred due to errors in a software update for the 213 upload portal, which were resolved by improvements implemented in the user side command 214 line interface software. Other data upload issues were identified and addressed in real time, including metadata file formatting errors, availability of upload clients for all required 215 216 operating systems, and user interface display errors preventing batch release.

217

#### 218 **Discussion**

This pilot study reveals the potential for cloud-based synchronous global data processing and analysis for public health. The GPAS platform provides an example of unified assembly, variant calling and analysis of data from participating centres, which can facilitate both local and globally aggregated analysis. In this cross-sectional observational study, the aggregate analysis conforms to contemporary observations of SARS-CoV-2 genetic

epidemiology[23,24,25,26,27], though these observations remain limited by global disparitiesin sequencing volume.

226

227 The opportunistic sampling frame used means this study is likely to be geographically 228 incomplete, but even with this limitation we observed cosmopolitan global mixing of 229 Omicron lineages between study sites. Even a BA.4 sub-lineage which demonstrated 230 extensive replacement in one geographical location (Chile) was not completely restricted to 231 that site and could be identified in a geographically distant site (United Kingdom). During the 232 period of the study, the United Kingdom site performed genomic sequencing on all clinical 233 isolates which had tested positive for SARS-CoV-2 on PCR, and despite being dominated by 234 BA.5, was also able to identify examples of a BA.2 sub-lineage that was otherwise restricted 235 to Vietnam. Such mixing is likely the result of movement for travel and migration, as SARS-236 CoV-2 related travel restrictions had been relaxed in the countries with participating sites.

237

238 Given evidence of global mixing and limited diversity between sites, viral genome 239 sequencing is limited in its ability to inform studies of local viral transmission in this 240 Omicron dominated era, where both rapid global mixing and transmission drives spread.[26] 241 Allowing for up to three different single nucleotide variants, the majority of isolates from the 242 dominant lineages BA.2, BA.4 and BA.5 had at least one closely related sample within each 243 countries' contemporaneously sequenced samples. Depending on lineage, between 10.0% 244 and 31.5% of genotypically identical sequences in this study were identified in different 245 countries and continents. The use of a shared bioinformatics analysis pipeline, as described 246 here, highlights how lineages can be simultaneously and confidently mapped across distant 247 sites. This captures the evidence of well described rapid global dispersal of Omicron lineages 248 with successive selective sweeps of these new Omicron variants over short time scales.[27] 249

These observations highlight the potential for deriving insights from viral sequencing at a fewglobally distributed sites. While this study pertains to a specific point in the pandemic, it

raises the question of how to better design genomic surveillance balancing the public health 252 253 need and available resources. It is recognised that a preponderance of sequence data came 254 from high-income countries, who sequenced a proportion of cases ten-fold higher than that 255 achieved in low- and middle-income counties during the first two years of the pandemic.[9] 256 Nor was the data collected evenly over the course of pandemic. In retrospect this was not 257 optimal. Better designed representative sampling would be immensely empowering and is 258 likely possible through well-designed and suitably powered sampling frames. Ideally, this 259 would be addressed through pandemic preparedness planning, enabling sequencing to be 260 focussed at selected sentinel sites globally cognisant of national jurisdictions and the benefit 261 of longitudinal data, as exemplified by a cohort design in the UK.[25]

262

Pathogen sequencing played a highly valuable role in the COVID-19 pandemic and remains a 263 264 critical global and national capability. This is highlighted by studies of viral transmission that have yielded important insights into the modes of pathogen spread.[1-5] In addition, 265 266 identification of emerging variants-of-concern guided public health and policy responses, [28] as well as informing assessments about the impact of emerging variants on the impact of 267 268 therapeutics (such as monoclonal antibodies) and vaccines.[7,29] The present cross-sectional 269 study has the limitation of lacking longitudinal data on how these findings changed over time. 270 Nevertheless, this study demonstrates how simply structured sampling across the world is 271 well placed to rapidly identify replacement by new lineages. The integration of genomic data 272 with subject disease manifestation and severity data would enable the ready investigation of 273 associations between genomic variation and severity of disease, as suggested by others [30] 274 and predictive modelling for anticipating the course of future epidemics as described so 275 effectively early in the SARS-CoV-2 pandemic [31].

276

The world is now better prepared to urgently initiate genomic pathogen surveillance. The available sequencing platform capacity is much improved, and the achievements of global data aggregation (illustrated by INSDC and GISAID databases) has alleviated a major

obstacle to effective genomic surveillance. A remaining obstacle is local turnkey 280 281 bioinformatics to perform sequence assembly, variant calling and analysis. These are needed 282 to deliver standardised and quality assured outputs – specifically the SARS-CoV-2 viral 283 sequence FASTA file – for phylogenetic analysis either for global analysis by an 284 international entity such as GISAID, or for local and national analyses. GPAS has developed 285 an exemplar cloud-based, web-enabled service design that is optimised for operation by a 286 laboratory scientist and removes dependence on in-laboratory bioinformatics expertise. Thus, 287 this work reveals the benefit of establishing software for simply and automatically ingesting 288 sequence data from a sequencer in a local lab and yielding data ready for local or 289 international analysis. A software infrastructure such as the GPAS platform fills a gap in 290 delivering global genomic surveillance. Flexible privacy protections allows users to control 291 sharing of genomic data. GPAS is freely available to low- and middle-income countries, 292 reducing some of the barriers to analysis services in low resource settings. Remaining 293 challenges include high speed computer network access and local epidemiological tools, and 294 expertise for detailed epidemiological analysis.

295

#### 296 Conclusions

The COVID-19 pandemic has demonstrated the multiple ways in which viral sequencing can inform pandemic responses, but resources and capabilities are not equitably distributed. A service like GPAS democratises SARS-CoV-2 genomics, enabling researchers and laboratories, regardless of their location or level of bioinformatics expertise, to participate actively in global surveillance efforts. By providing accessible and user-friendly tools for sequence assembly, lineage assignment, and data sharing, it fosters collaboration, harmonises data, and ultimately enhances pandemic preparedness.

304

## **306** Funding statement

307	GPAS is free at the point of use for users in low- and middle-income countries. GPAS was
308	developed specifically to minimise the need for bioinformatics staff (a scarce and expensive
309	resource), to help bring genomic insights within reach for laboratories with limited resources.
310	
311	GPAS operates as a non-profit organisation. All GPAS SARS-CoV-2 services were offered
312	free of charge to all sites for the purposes of this study. Staff costs for the 5C analysis team
313	were met by the University of Oxford.
314	
315	The cloud infrastructure used in this study was donated by Oracle Corporation.
316	
317	Sequencing activities for NICD are supported by a conditional grant from the South African
318	National Department of Health as part of the emergency COVID-19 response; a cooperative
319	agreement between the National Institute for Communicable Diseases of the National Health
320	Laboratory Service and the United States Centers for Disease Control and Prevention
321	(NU51IP000930); the South African Medical Research Council (SAMRC) with funds
322	received from the South African Department of Science and Innovation; the African Society
323	of Laboratory Medicine (ASLM) and Africa Centers for Disease Control and Prevention
324	through a sub-award from the Bill and Melinda Gates Foundation grant number INV-018978;
325	Africa PGI, the UK Foreign, Commonwealth and Development Office and Wellcome (Grant
326	no 221003/Z/20/Z); and the Department of Health and Social Care's Fleming Fund using UK
327	aid NICD sequencing was also supported by The Coronavirus Aid, Relief, and Economic
328	Security Act (CARES ACT) through the Centers for Disease Control and Prevention (CDC)
329	and the COVID International Task Force (ITF) funds through the CDC under the terms of a
330	subcontract with the African Field Epidemiology Network (AFENET) AF-NICD-001/2021.

- 331 Genomic surveillance conducted in Vietnam was supported by the Wellcome Trust
- 332 (222574/Z/21/Z). L.V.T. is supported by the Wellcome Trust of Great Britain
- 333 (204904/Z/16/Z and 226120/Z/22/Z).
- 334

#### 335 Ethical statement

- 336 SARS-CoV-2 sequencing was performed for public health surveillance and ethical approval
- 337 for secondary analysis was not required. This determination was reviewed by the University
- 338 of Oxford Joint Research Office. No patient identifying information was shared as part of this
- 339 study. Sample identifiers remain with the submitter, and are never kept on GPAS or shared
- 340 with other users. GPAS generates identifiers for each sequence and writes a file linking
- anonymised ID to the submitted identifiers. Only the user submitting sequence data has
- 342 access to these records. The GPAS upload client selects only SARS-CoV-2 sequence reads
- 343 and discards non SARS-CoV-2 reads (including all human sequences).

344

#### 345 Data availability

- 346 Submitted sequencing reads (free from human reads) for all included samples are available
- 347 from European Nucleotide Archive study accession PRJEB70597.

348

#### 349 **Conflicts of interest**

- 350 AvG and NW have received grant funding from Sanofi and The Bill and Melinda Gates
- 351 Foundation.
- 352

#### 353 Authors

354 All authors have seen and approved the manuscript

- 356 Acknowledgments
- Microbial Genomics Reference Laboratory, New South Wales Health Pathology,
- 358 Sydney, Australia

359	•	El Instituto de Salud Pública de Chile, Chile
360	•	Centre for Respiratory Diseases and Meningitis (CRDM), National Institute for
361		Communicable Diseases (NICD), a division of the National Health Laboratory
362		Service, South Africa
363	•	The Institut Pasteur de Dakar, Senegal
364	•	Oxford University Hospitals NHS Trust, Oxford, United Kingdom
365	•	University of Virginia, Charlottesville, United States of America
366	•	Oxford University Clinical Research Unit, Vietnam
367	•	Hospital for Tropical Diseases SARS-CoV-2 testing team, HTD Vietnam: Le
368		Manh Hung, Nguyen Le Nhu Tung, Nguyen Thanh Phong, Vo Minh Quang,
369		Pham Thi Ngoc Thoa, Nguyen Thanh Truong, Tran Nguyen Phuong Thao,
370		Dao Phuong Linh, Ngo Tan Tai, Ho The Bao, Vo Trong Vuong, Huynh Thi
371		Kim Nhung
372	•	Oracle Global Health Business Unit
373		
374	Refer	ences
375	1.	Li J, Lai S, Gao GF, Shi W. The emergence, genomic diversity and global spread of
376		SARS-CoV-2. Nature. 2021 Dec;600(7889):408-418. doi: 10.1038/s41586-021-
377		04188-6.
378	2.	Wilkinson E, Giovanetti M, Tegally H, San JE, Lessells R, Cuadros D, et al. A year of
379		genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa.
380		Science. 2021 Oct 22;374(6566):423-431. doi: 10.1126/science.abj4336.
381	3.	McCrone JT, Hill V, Bajaj S, Pena RE, Lambert BC, Inward R, et al. Context-specific
382		emergence and growth of the SARS-CoV-2 Delta variant. Nature. 2022
383		Oct;610(7930):154-160. doi: 10.1038/s41586-022-05200-3.
384	4.	Raghwani J, du Plessis L, McCrone JT, Hill SC, Parag KV, Thézé J, et al. Genomic
385		Epidemiology of Early SARS-CoV-2 Transmission Dynamics, Gujarat, India. Emerg
386		Infect Dis. 2022 Apr;28(4):751-758. doi: 10.3201/eid2804.212053.

387	5.	Snell LB, Fisher CL, Taj U, Stirrup O, Merrick B, Alcolea-Medina A, et al.
388		Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2
389		infection early in the pandemic and the role of unidentified cases in transmission. Clin
390		Microbiol Infect. 2022 Jan;28(1):93-100. doi: 10.1016/j.cmi.2021.07.040
391	6.	Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The
392		biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev
393		Genet. 2021 Dec;22(12):757-773. doi: 10.1038/s41576-021-00408-x.
394	7.	Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn HM, Selvaraj M, et
395		al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and
396		BA.1 serum. Cell. 2022 Jul 7;185(14):2422-2433.e13. doi:
397		10.1016/j.cell.2022.06.005. Epub 2022 Jun 9. PMID: 35772405; PMCID:
398		PMC9181312.
399	8.	Merhi G, Koweyes J, Salloum T, Khoury CA, Haidar S, Tokajian S. SARS-CoV-2
400		genomic epidemiology: data and sequencing infrastructure. Future Microbiol. 2022
401		Sep;17:1001-1007. doi: 10.2217/fmb-2021-0207.
402	9.	Brito AF, Semenova E, Dudas G, Hassler GW, Kalinich CC, Kraemer MUG, et al.
403		Global disparities in SARS-CoV-2 genomic surveillance. Nat Commun. 2022 Nov
404		16;13(1):7003. doi: 10.1038/s41467-022-33713-y
405	10.	Global genomic surveillance strategy for pathogens with pandemic and epidemic
406		potential, 2022–2032. Geneva: World Health Organization; 2022. Licence: CC BY-
407		NC-SA 3.0 IGO
408	11.	Inzaule SC, Tessema SK, Kebede Y, Ogwell Ouma AE, Nkengasong JN. Genomic-
409		informed pathogen surveillance in Africa: opportunities and challenges. Lancet Infect
410		Dis. 2021 Sep;21(9):e281-e289. doi: 10.1016/S1473-3099(20)30939-7
411	12.	Chen Z, Azman AS, Chen X, Zou J, Tian Y, Sun R, et al. Global landscape of SARS-
412		CoV-2 genomic surveillance and data sharing. Nat Genet. 2022 Apr;54(4):499-507.
413		doi: 10.1038/s41588-022-01033-y.

414	13. Ohlsen EC, Hawksworth AW, Wong K, Guagliardo SAJ, Fuller JA, Sloan ML, et al.
415	Determining Gaps in Publicly Shared SARS-CoV-2 Genomic Surveillance Data by
416	Analysis of Global Submissions. Emerg Infect Dis. 2022 Dec;28(13):S85-S92. doi:
417	10.3201/eid2813.220780.
418	14. Hunt M, Swann J, Constantinides B, Fowler PW, Iqbal Z. ReadItAndKeep: rapid
419	decontamination of SARS-CoV-2 sequencing reads. Bioinformatics. 2022 Jun
420	13;38(12):3291-3293. doi: 10.1093/bioinformatics/btac311.
421	15. https://github.com/iqbal-lab-org/viridian_workflow/wiki
422	16. Aksamentov I, Roemer C, Hodcroft EB, Neher RA. Nextclade: clade assignment,
423	mutation calling and quality control for viral genomes. Journal of Open Source
424	Software, 2021 6(67): 3773, https://doi.org/10.21105/joss.03773
425	17. O'Toole Á, Scher E, Underwood A, Jackson B, Hill V, McCrone JT, et al.
426	Assignment of epidemiological lineages in an emerging pandemic using the pangolin
427	tool. Virus Evol. 2021 Jul 30;7(2):veab064. doi: 10.1093/ve/veab064.
428	18. <u>https://github.com/connor-lab/aln2type</u>
429	19. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus
430	associated with human respiratory disease in China. Nature. 2020
431	Mar;579(7798):265-269. doi: 10.1038/s41586-020-2008-3
432	20. Mazariegos-Canellas O, Do T, Peto T, Eyre DW, Underwood A, Crook D, et al
433	BugMat and FindNeighbour: command line and server applications for investigating
434	bacterial relatedness. BMC Bioinformatics. 2017 Nov 13;18(1):477. doi:
435	10.1186/s12859-017-1907-2.
436	21. https://github.com/davidhwyllie/findNeighbour4
437	22. Stamatakis A. RAxML version 8: A tool for phylogenetic analysis and post-analysis
438	of large phylogenies Bioinformatics. 2014; 30(9),1312-3 doi:
439	10.1093/bioinformatics/btu033.
440	23. World Health Organisation Coronavirus (COVID-19) Dashboard,
441	https://covid19.who.int [Accessed 19th April 2023]

442	24.	Tosta S, Moreno K, Schuab G, Fonseca V, Segovia FMC, Kashima S, et al. Global
443		SARS-CoV-2 genomic surveillance: What we have learned (so far). Infect Genet
444		Evol. 2023 Mar;108:105405. doi: 10.1016/j.meegid.2023.105405.
445	25.	Foulkes S, Monk EJM, Sparkes D, Hettiarachchi N, Milligan ID, Munro K, et al.
446		Early Warning Surveillance for SARS-CoV-2 Omicron Variants, United Kingdom,
447		November 2021-September 2022. Emerg Infect Dis. 2023 Jan;29(1):184-188. doi:
448		10.3201/eid2901.221293.
449	26.	Xu Y, Liu T, Li Y, Wei X, Wang Z, Fang M, et al. Transmission of SARS-CoV-2
450		Omicron Variant under a Dynamic Clearance Strategy in Shandong, China. Microbiol
451		Spectr. 2023 Mar 14;11(2):e0463222. doi: 10.1128/spectrum.04632-22.
452	27.	Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, et al. The
453		evolution of SARS-CoV-2. Nat Rev Microbiol. 2023 Apr 5. doi: 10.1038/s41579-
454		023-00878-2.
455	28.	WHO Technical Advisory Group on SARS-CoV-2 Virus Evolution, Updated working
456		definitions and primary actions for SARS-Cov-2 variants, World Health Organisation,
457		March 2023. https://www.who.int/publications/m/item/updated-working-definitions-
458		and-primary-actions-forsars-cov-2-variants [Accessed 19th April, 2023]
459	29.	Aggarwal A, Akerman A, Milogiannakis V, Silva MR, Walker G, Stella AO, et al.
460		SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral
461		responses and resistance to clinical immunotherapeutics relative to viral variants of
462		concern. EBioMedicine. 2022 Oct;84:104270. doi: 10.1016/j.ebiom.2022.104270.
463	30.	Oude Munnink BB, Worp N, Nieuwenhuijse DF, Sikkema RS, Haagmans B,
464		Fouchier RAM, et al The next phase of SARS-CoV-2 surveillance: real-time
465		molecular epidemiology. Nat Med. 2021 Sep;27(9):1518-1524. doi: 10.1038/s41591-
466		021-01472-w.
467	31.	Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing
468		transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021
469		May;593(7858):266-269. doi: 10.1038/s41586-021-03470-x.

## 470 Figures





472

473



```
sub-lineage within each study site, where collection date was in June or July 2022.
```





477

Figure 2: Maximum likelihood phylogeny of isolates from each major lineage (BA.2, BA.4, 478 479 BA.5) found in seven centres. Final branches are coloured according the centre in which they 480 were sequenced.





482

483 Figure 3: Percentage of related samples which are restricted to the same study site, allowing for 0, 1, 2 and 3 SNVS as the threshold for relatedness, for 3 major lineages (BA.2, BA.4 and 484 485 BA.5).



490 according to submitting site (a) all samples and (b) samples processed in under 1000 minutes 491